The researchers noted that most genomic analyses have traditionally focused on commonly mutated genes, which can pinpoint mutations occurring most frequently but does not account for the extent to which these mutations impact cancer cell survival and proliferation.
In Acute Leukemia, Chance of Response Is Patient’s Top Concern
Review of Posttransplant Strategies for AML Relapse Prevention
HMA Therapy Translates to More Time at Home for Patients With AML
Induction Treatment Based on Pharmacogenomics May Address Racial Disparities in AML
Certain Low-Prevalence Mutations May Be Strong Drivers in Pediatric ALL
Inotuzumab Ozogamicin Plus Dose-Adjusted EPOCH: Promise in R/R B-ALL
Consolidative Radiotherapy a Potential Treatment for Extramedullary AML
Ponatinib, Imatinib Face Off, but Still Room for TKI Improvement in Ph+ ALL
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Case Report Demonstrates Nuanced Decisions in Treating ALL Relapse With Skull Base Lesion
Study Shows Improvements in Posttransplant Outcomes Among Older Patients With AML
Age Alone Is No Barrier to Allo-HCT for AML, Data Indicate
In AML, CAR T-Cell Therapy Has Higher CR Rate After Transplant
Revumenib Earns FDA Priority Review in R/R KMT2Ar Acute Leukemia
Post Treatment, Children With ALL Experience Long-Term Fatigue
Diagnosis, Treatment Remain Challenges for Chronic Disseminated Candidiasis in Acute Leukemia
FDA Grants Accelerated Approval to Ponatinib Plus Chemotherapy in First-Line Ph+ ALL
Research Into Reactive Oxygen Species Could Help Address AML Treatment Resistance
Case Series Highlights Bacillus Cereus Risk in Patients With AML, Neutropenia
Pediatric AML Preclinical Pipeline Boosted by Xenograft Models
Methotrexate—but Not Glucocorticoids—Affects BMD in Patients With ALL
COVID-19–Related Chemotherapy Delays Common in Pediatric Patients With Acute Lymphoblastic Leukemia or Lymphoma
Genomic Testing Is Worth the Wait When Balanced Against Cost of the Wrong Therapy
Geographic, Sociodemographic Factors Significantly Influence AML in Elderly Patients
Research Indicates In Utero Origins of Acute Leukemia in Children
In AML, Immunotherapy Shows Promise to Expand Treatment Toolbox
ELN Risk Category, MRD Status Predictive of Relapse in Patients With AML
Increased Fatigue Associated With Greater Risk of Mortality Among Patients With AML, ALL, MDS
ASH 2023: Coverage of ALL
Findings Suggest Utility of Specialized MRD Testing in Management of FLT3-ITD AML With Quizartinib
alloHSCT Yields Benefits in R/R AML Regardless of Leukemia Burden
Health Care Resource Use, Cost Burden Appear Substantial in R/R B-Cell ALL
High Disease Burden at Acute Leukemia Diagnosis More Common in Black Children, Study Finds
High LDH Levels Associated With Worse Survival in Newly Diagnosed AML
AML-Specific Early Mortality Risk Indices May Increase Accuracy of Care Quality Measurements
